RxDoctor Payments Data

Julianne Bender

Psychiatric/Mental Health · Lansing, MINPI 1427610690

Payments from drug & device makers

$2,680in general payments, 2019–2025

Across 137 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$731
  • Otsuka America Pharmaceutical, Inc.$419
  • Sunovion Pharmaceuticals Inc.$323
  • Jazz Pharmaceuticals Inc.$259
  • AbbVie$227
  • Johnson & Johnson$187
  • plus $535 from 7 others

What the payments were for

  • Food & beverage$2,62998%
  • Education$502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,680 in reported general payments places this provider in the 80th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Medicare billing

Part B allowed, 2024
$20,288
Medicare patients
24
Services billed
228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuvelityDextromethorphan Hbr/Bupropion19$31,292
BelsomraSuvorexant13$11,000
Bupropion XlBupropion Hcl103$4,525
Desvenlafaxine Succinate ErDesvenlafaxine Succinate44$4,207
Methylphenidate ErMethylphenidate Hcl27$4,129
Lamotrigine101$3,039
Duloxetine Hcl57$2,034
Quetiapine Fumarate53$1,674
Venlafaxine Hcl ErVenlafaxine Hcl33$1,643
Ziprasidone Hcl22$1,559
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine57$1,473
Escitalopram Oxalate75$1,215
Buspirone Hcl32$1,169
Trazodone Hcl58$1,046
Fluoxetine Hcl46$840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Axsome Therapeutics, Inc.Auvelity$18$31,29219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →